(Q38222814)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Mavoglurant as a treatment for Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Alberto Lazarowski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jaume Folch

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Antoni Camins

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Dmitry Petrov

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Ignacio Pedros

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Maria Luisa de Lemos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anna Maria Canudas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carlos Beas-Zarate

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carme Auladell

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

24 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1165-1179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic prospects for Parkinson disease

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The pathophysiological basis of sensory disturbances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Dealing with the devil in the detail - some thoughts about the next model of the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Striatal glutamatergic mechanisms and extrapyramidal movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Glutamate receptors as therapeutic targets for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Trials of neuroprotective therapies for Parkinson's disease: problems and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Protection against Parkinson's disease progression: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The evidence for disease modification in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Drug therapy in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Medical management of Parkinson's disease: focus on neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The promiscuous mGlu5 receptor--a range of partners for therapeutic possibilities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptors: physiology, pharmacology, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Developmental regulation of metabotropic glutamate receptor 5b protein in rodent brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

The mGlu5 receptor antagonist MTEP attenuates opiate self-administration and cue-induced opiate-seeking behaviour in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

mGlu5 negative allosteric modulators: a patent review (2010-2012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Role of metabotropic glutamate receptors in the mechanisms of experimental parkinsonism development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Pharmacokinetic evaluation of eltoprazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Development of mavoglurant and its potential for the treatment of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Intracellular mGluR5 can mediate synaptic plasticity in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.931370

10.1517/13543784.2014.931370

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json

release_vs7bmxczxjc5lavrcjvcemvlsi

21 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vs7bmxczxjc5lavrcjvcemvlsi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960254%20AND%20SRC:MED&resulttype=core&format=json